Codexis, Inc. (CDXS)
CDXS Stock Price Chart
Explore Codexis, Inc. interactive price chart. Choose custom timeframes to analyze CDXS price movements and trends.
CDXS Company Profile
Discover essential business fundamentals and corporate details for Codexis, Inc. (CDXS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Apr 2010
Employees
188.00
Website
https://www.codexis.comCEO
Alison Moore
Description
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
CDXS Financial Timeline
Browse a chronological timeline of Codexis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.17, while revenue estimate is $13.82m.
Earnings released on 7 May 2026
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $15.25m , beating expectations by +4.97%.
Earnings released on 11 Mar 2026
EPS came in at $0.11 surpassing the estimated $0.01 by +1.00k%, while revenue for the quarter reached $38.92m , beating expectations by +8.61%.
Earnings released on 6 Nov 2025
EPS came in at -$0.22 falling short of the estimated -$0.15 by -46.67%, while revenue for the quarter reached $8.60m , missing expectations by -76.00%.
Earnings released on 13 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $15.33m , missing expectations by -21.31%.
Earnings released on 14 May 2025
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%, while revenue for the quarter reached $7.54m , missing expectations by -21.94%.
Earnings released on 27 Feb 2025
EPS came in at -$0.13 falling short of the estimated -$0.04 by -225.00%, while revenue for the quarter reached $21.46m , missing expectations by -21.71%.
Earnings released on 31 Oct 2024
EPS came in at -$0.29 falling short of the estimated -$0.25 by -16.00%, while revenue for the quarter reached $12.83m , missing expectations by -53.18%.
Earnings released on 8 Aug 2024
EPS came in at -$0.32 falling short of the estimated -$0.26 by -23.08%, while revenue for the quarter reached $7.98m , beating expectations by +2.03%.
Earnings released on 2 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $17.07m , beating expectations by +24.99%.
Earnings released on 28 Feb 2024
EPS came in at $0.02 surpassing the estimated -$0.16 by +112.50%, while revenue for the quarter reached $26.56m , beating expectations by +33.47%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%, while revenue for the quarter reached $9.28m , missing expectations by -7.51%.
Earnings released on 3 Aug 2023
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $21.32m , beating expectations by +1.15%.
Earnings released on 4 May 2023
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $12.98m , missing expectations by -7.86%.
Earnings released on 23 Feb 2023
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $30.38m , beating expectations by +4.99%.
Earnings released on 3 Nov 2022
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%, while revenue for the quarter reached $34.47m , beating expectations by +11.41%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $38.41m , beating expectations by +0.79%.
Earnings released on 5 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $35.34m , beating expectations by +23.62%.
Earnings released on 24 Feb 2022
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $24.50m , beating expectations by +5.59%.
Earnings released on 4 Nov 2021
EPS came in at $0.03 surpassing the estimated -$0.09 by +133.33%, while revenue for the quarter reached $36.77m , beating expectations by +29.01%.
Earnings released on 5 Aug 2021
EPS came in at -$0.07 surpassing the estimated -$0.17 by +58.82%, while revenue for the quarter reached $25.45m , beating expectations by +38.78%.
CDXS Stock Performance
Access detailed CDXS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
